RBC Capital Reiterates Outperform Rating on Regeneron Pharma (REGN)

May 17, 2024 1:43 PM EDT Send to a Friend
RBC Capital analyst Brian Abrahams reiterated an Outperform rating and $1,185.00 price target on Regeneron Pharma (NASDAQ: REGN)The analyst comments ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login